<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428165</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-02/SH-01</org_study_id>
    <nct_id>NCT03428165</nct_id>
  </id_info>
  <brief_title>Transfer of Frozen Embryos in Natural Cycle: Evaluation of Impact of Spontaneous Versus HCG-triggered Ovulation on Pregnancy Rate</brief_title>
  <acronym>TECNAT</acronym>
  <official_title>Transfer of Frozen Embryos in NATural Cycle: Evaluation of Impact of Spontaneous Versus HCG-triggered Ovulation on Pregnancy Rate - Bicentric Prospective Open Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluated whether there is a difference in pregnancy rate when
      transferring frozen embryos between patietns having spontaneously ovulated versus those
      triggered to voulate with HCG.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate after transfer of frozen embryos at day 14 between groups</measure>
    <time_frame>Day 14</time_frame>
    <description>Yes/no; Blood ßHCG &gt; 100UI/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Yes/no; ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate within first 12 weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Yes/no; ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth</measure>
    <time_frame>At delivery, maximum week 42</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy term</measure>
    <time_frame>At delivery, maximum week 42</time_frame>
    <description>Weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>At delivery, maximum week 42</time_frame>
    <description>Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation of transfer due to premature ovulation (progesterone &gt;3ng/ml and/or Luteinizing hormone &gt; 3-fold base level)</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits for endometrial preparation until attaining LH peak</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>in Vitro Fertilization</condition>
  <arm_group>
    <arm_group_label>human chorionic gonadotropin (HCG)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>spontaneous</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HCG</intervention_name>
    <description>250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono</description>
    <arm_group_label>human chorionic gonadotropin (HCG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient is aged between 18 and 40

          -  Patient has regular cycles and classified as 'easy' for transfer of a frozen embryo at
             blastocyste stage (vitrification day 5)

        Exclusion Criteria:

          -  The subject is participating in an interventional study, or is in a period of
             exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  Patient using donated oocytes

          -  Necessity of pre-implantation diagnosis

          -  Patients with stage 3 or 4 endometriosis or adenomyosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie Huberlant</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie Huberlant</last_name>
    <phone>+33 (0)4.66.68.32.20</phone>
    <email>stephanie.huberlant@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tal Anahory, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tal Anahory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir Hamamah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Bringer Deutsch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Vincens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Vintejoux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile Brunet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Huberlant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Rougier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsa Maris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Letouzey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Laure Tailland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

